PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Reference is made to the stock exchange release published by Arctic Bioscience 30th January 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience.
On 3rd February 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company's General Meeting on 26th April 2024, resolved to increase the share capital from NOK 2 536 955,20 to NOK 2 581 598,00 by issuance of 446 428 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,24 per share, including a share premium of NOK 2,14 per share. Further, the Board resolved to increase the share capital from NOK 2 581 598,00 to NOK 2 668 934,00 by issuance of 873 360 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,29 per share, including a share premium of NOK 2,19 per share.
The total amount allocated as share premium is NOK 2 868 014,32. The total subscription amount is NOK 2 999 993,12. Following the registration of this share capital increase in the Norwegian Register of Business Enterprises, the Company's share capital will be NOK 2 668 934 divided into 26 689 340 shares, each having a nominal value of NOK 0,10.
Minutes from Board Meeting and statement regarding capital increase are attached hereto.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.